Adam Bograd

Research Fellow

Adam Bograd

Research Fellow

Awards and Scholarships

NIH T-32 Research Fellowship

Current Employment

Thoracic Surgery Fellow, Memorial Sloan Kettering Cancer Center, New York, NY

Publications

Manuscripts

  • Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K,  Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-free and Overall Survival in Early-Stage Lung Adenocarcinoma. Clin Cancer Res. 2014 Feb 15;20(4):1020-8. PMID: 24334761; PMCID: PMC3944669.
  • Nitadori JI, Bograd AJ, Morales EA, Rizk NP, Dunphy MP, Sima CS, Rusch VW, Adusumilli PS. Preoperative Consolidation-to-Tumor Ratio and SUVmax Stratify the  Risk of Recurrence in Patients Undergoing Limited Resection for Lung Adenocarcinoma ≤2 cm. Ann Surg Oncol. 2013 Dec;20(13):4282-8. PMID: 23955584.
  • Nitadori J, Bograd AJ, Kadota K, Sima CS, Rizk NP, Morales EA, Rusch VW, Travis WD, Adusumilli PS. Impact of Micropapillary Histologic Subtype in Selecting Limited Resection vs Lobectomy for Lung Adenocarcinoma of 2cm or Smaller. J Natl Cancer Inst. 2013 Aug 21;105(16):1212-20. PMID: 23926067; PMCID: PMC3748005.
  • Servais EL, Colovos C, White J, Bograd AJ, Sadelain M, Adusumilli PS. Animal models and molecular imaging tools to investigate lymph node metastases. J Mol Med 2011 Aug;89(8):753-69. PMID 21556810.
  • Servais EL, Colovos C, Rodriguez LA, Bograd AJ, Nitadori JI, Sima CS, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 2012;18(9):2478-89. PMID 22371455.
  • Bograd A, Suzuki K, Vertes E, Colovos C, Morales E, Sadelain M, Adusumilli PS. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 2011 Nov;60(11):1509-27. PMID 21913025.

Abstracts/Presentations  

  • Bograd A, Villena-Vargas J, Kachala S, Servais E, Colovos C, Rodriguez L, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin-targeted T-cell therapy optimized for the lung adenocarcinoma tumor microenvironment. International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer, October 27-30, 2013, Sydney, Australia.
  • Bograd A, Kadota K, Lee MC, Sarkaria IS, Rusch VW, Travis WD, Adusumilli PS. Tumoral neutral endopeptidase (CD10) expression predicts risk of recurrence, and further stratify intermediate-grade histology patients in stage I lung adenocarcinoma. International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer, October 27-30, 2013, Sydney, Australia.
  • Kachala S, Bograd AJ, Rodriguez L, Servais EL, Kadota K, Sima C, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin decreases recurrence-free survival in lung adenocarcinoma by imparting an aggressive phenotype. American Association for Thoracic Surgery meeting. May 4-8, 2013; Minneapolis. MN (Oral Presentation).
  • Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, Sadelain M, Rusch VW, Adusumilli PS. Mesothelin promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in malignant pleural mesothelioma (MPM) patients: a potential mechanism for MPM regional aggressiveness. American Association for Thoracic Surgery 2012, Lillehei Forum, May 2012, San Francisco, CA.
  • Servais EL, Nitadori J, Morales EA, Suzuki K, Bograd AJ, Rizk NP, Downey RJ, Rusch VW, Adusumilli PS. Pre-operative consolidation to tumor ratio on computed tomography and FDG-PET SUVmax predict recurrence after limited resection of early lung adenocarcinoma. American Association for Thoracic Surgery 2012, May 2012, San Francisco, CA.